QuidelOrtho Corporation (QDEL)

Market Cap	2.35B
Revenue (ttm)	2.78B
Net Income (ttm)	-2.05B
Shares Out	67.45M
EPS (ttm)	-30.54
PE Ratio	n/a
Forward PE	15.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	440,331
Open	35.13
Previous Close	35.87
Day's Range	34.45 - 35.90
52-Week Range	29.74 - 49.45
Beta	0.10
Analysts	Buy
Price Target	51.20 (+46.75%)
Earnings Date	May 7, 2025

About QDEL

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease,...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1979
• Employees: 6,600
• Stock Exchange: NASDAQ
• Ticker Symbol: QDEL
• Website: https://www.quidelortho.com

Financial Performance

In 2024, QuidelOrtho's revenue was $2.78 billion, a decrease of -7.17% compared to the previous year's $3.00 billion. Losses were -$2.05 billion, 20216.8% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for QDEL stock is "Buy." The 12-month stock price forecast is $51.2, which is an increase of 46.75% from the latest price.

Price Target

$51.2

(46.75% upside)

Analyst Consensus: Buy